NPM1 ‐mutated AML : One entity, multiple layers of heterogeneity
British Journal of Haematology · 2026-11-11
DOI: 10.1111/bjh.70954 ↗Abstract
Nucleophosmin 1 ( NPM1 ) mutations are found in around one third of all acute myeloid leukaemias (AMLs). However, little is known about the clinical role of the rare, non‐A NPM1 variants. Sangiorgio et al. showed that rare variants shared a similar molecular background and overall survival to the common type A, with FMS‐like tyrosine kinase 3 ( FLT3 ) status as the main determinant of outcome. Commentary on: Sangiorgio et al. Rare variants of NPM1 mutations share a similar molecular background to the common NPM1 type A variant and are associated with similar survival in adults with acute myeloid leukaemia. Br J Haematol 2026 (Online ahead of print). doi: 10.1182/blood‐2024‐202884 .
EUVIMED